Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143864 | 0.83 | ALDH1A1 (0.48) | ALDH1A1TSHRMAPTHPGDKDM4E | |
| SCHEMBL25518005 | 0.79 | MAPT (0.37) | ALDH1A1TSHRMAPTHPGDKDM4E | |
| SCHEMBL2641952 | 0.78 | ERN1 (0.52) | ALDH1A1MCL1ERN1 | |
| SCHEMBL7493216 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTHPGDKDM4E | |
| SCHEMBL6894572 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTHPGDKDM4E | |
| SCHEMBL2800253 | 0.75 | ALDH1A1 (0.48) | ALDH1A1TSHRMAPTHPGDKDM4E | |
| SCHEMBL7089541 | 0.75 | ALDH1A1 (0.52) | ALDH1A1TSHRHPGDKDM4EGAA | |
| SCHEMBL23754494 | 0.73 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTHPGDKDM4E | |
| SCHEMBL5776519 | 0.73 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTHPGDKDM4E | |
| SCHEMBL31423173 | 0.73 | ALDH1A1 (0.47) | ALDH1A1TSHRMAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563799-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563799-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| EP-1919918-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-20070049598-A1 | p38 Map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049598-A1 | p38 Map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| WO-2007023111-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049598-A1 | p38 Map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| WO-2007023111-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | ALDH1A1 1291/4885TSHR 2103/4885MAPT 762/4885 |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | SLC6A7, SLC6A5, SLC1A2 | ALDH1A1 1381/4885TSHR 1584/4885MAPT 441/4885 |
| US-20070049598-A1 | p38 Map kinase inhibitors and methods for using the same | MAPK1, MAPK3, MAP3K1 | ALDH1A1 2948/4885TSHR 1898/4885MAPT 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.